{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:15:38Z","timestamp":1792512938615,"version":"4.5.0"},"reference-count":190,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors, also known as gliflozins, are a class of antidiabetic agents that act independently of insulin by promoting renal glucose excretion. They modulate glucose reabsorption in proximal renal tubules. Initially, they were used for the treatment of type 2 diabetes mellitus (T2DM); however, numerous pleiotropic benefits beyond glycemic control were observed. Large clinical trials confirmed their efficacy in reducing cardiovascular mortality, heart failure hospitalizations, and progression of chronic kidney disease. SGLT2 inhibitors reduce oxidative stress and inflammation and induce favorable metabolic adaptations, including lowering ketosis and upregulation of erythropoiesis. They also exert protective effects on hepatic and cognitive function. Additionally, SGLT2 inhibitors lower serum uric acid and reduce adipose tissue mass, which usually results in weight loss. Although generally well-tolerated, they are associated with increased risk of urogenital infections, euglycemic ketoacidosis, and a potentially enlarged amputation risk. Current guidelines worldwide recommend their use not only for T2DM but also for heart failure and chronic kidney disease, marking a paradigm shift toward organ-protective therapies. This review provides a comprehensive synthesis of current evidence on the mechanisms, clinical benefits, and safety profile of SGLT2 inhibitors, highlighting their expanding role in cardiometabolic and multisystem disease management.<\/jats:p>","DOI":"10.3390\/molecules30204125","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:44:10Z","timestamp":1760957050000},"page":"4125","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Sodium-Glucose Cotransporter-2 Inhibitors in Diabetes and Beyond: Mechanisms, Pleiotropic Benefits, and Clinical Use\u2014Reviewing Protective Effects Exceeding Glycemic Control"],"prefix":"10.3390","volume":"30","author":[{"given":"Julia","family":"Hanke","sequence":"first","affiliation":[{"name":"Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine\u2014National Research Institute, 128 Szaser\u00f3w Street, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1447-2917","authenticated-orcid":false,"given":"Katarzyna","family":"Romejko","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine\u2014National Research Institute, 128 Szaser\u00f3w Street, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8151-860X","authenticated-orcid":false,"given":"Stanis\u0142aw","family":"Niemczyk","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine\u2014National Research Institute, 128 Szaser\u00f3w Street, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 Inhibition\u2014A Novel Strategy for Diabetes Treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Fonseca-Correa, J.I., and Correa-Rotter, R. (2021). Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front. Med., 8.","DOI":"10.3389\/fmed.2021.777861"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejps.2016.08.025","article-title":"Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: Current Status and Future Perspective","volume":"93","author":"Madaan","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects with Type 2 Diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-Glucose Co-Transporters and Their Inhibition: Clinical Physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","article-title":"SGLT2-Selective Inhibitor Ipragliflozin Reduces Body Fat Mass by Increasing Fatty Acid Oxidation in High-Fat Diet-Induced Obese Rats","volume":"727","author":"Yokono","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_7","first-page":"216","article-title":"Weight Loss Effect of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients with Obesity without Diabetes: A Systematic Review","volume":"18","author":"Pratama","year":"2022","journal-title":"Acta Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 Inhibitors for the Prevention of Kidney Failure in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","first-page":"23","article-title":"The 2023 ESC Heart Failure Guideline Update and Its Implications for Clinical Practice","volume":"31","author":"Rashed","year":"2024","journal-title":"Br. J. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.2337\/dc24-S011","article-title":"American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142024","volume":"47","author":"Care","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/IJNRD.S268811","article-title":"SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients","volume":"13","author":"Nadkarni","year":"2020","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/jdi.13237","article-title":"Effects of Sodium\u2013Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials","volume":"11","author":"Xing","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhou, P., Tan, Y., Hao, Z., Xu, W., Zhou, X., and Yu, J. (2023). Effects of SGLT2 Inhibitors on Hepatic Fibrosis and Steatosis: A Systematic Review and Meta-Analysis. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1144838"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5114\/ceh.2020.102173","article-title":"SGLT2 Inhibitors for Improving Hepatic Fibrosis and Steatosis in Non-Alcoholic Fatty Liver Disease Complicated with Type 2 Diabetes Mellitus: A Systematic Review","volume":"6","author":"Dwinata","year":"2020","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/13872877251329474","article-title":"Neuroprotective Effects of SGLT2 Inhibitors Empagliflozin and Dapagliflozin on A\u03b21-42-Induced Neurotoxicity and Neuroinflammation in Cellular Models of Alzheimer\u2019s Disease","volume":"105","author":"Alami","year":"2025","journal-title":"J. Alzheimers Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Pawlos, A., Broncel, M., Wo\u017aniak, E., and Gorzelak-Pabi\u015b, P. (2021). Neuroprotective Effect of SGLT2 Inhibitors. Molecules, 26.","DOI":"10.3390\/molecules26237213"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000543533","article-title":"The Impact of SGLT2 Inhibitors on Dementia Onset in Patients with Type 2 Diabetes: A Meta-Analysis of Cohort Studies","volume":"115","author":"Pan","year":"2025","journal-title":"Neuroendocrinology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/eurheartj\/ehab765","article-title":"SGLT2 Inhibitors: The Statins of the 21st Century","volume":"43","author":"Braunwald","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.34067\/KID.0002772021","article-title":"SGLT2 Inhibitors: Physiology and Pharmacology","volume":"2","author":"Wright","year":"2021","journal-title":"Kidney360"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: A Review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_28","first-page":"134","article-title":"Josef von Mering: The Baron Who Discovered SGLT Inhibition","volume":"Volume 29","author":"Porta","year":"2020","journal-title":"Frontiers in Diabetes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of Hyperglycemia with Phlorizin Normalizes Tissue Sensitivity to Insulin in Diabetic Rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/sj.bjp.0703829","article-title":"Improved Diabetic Syndrome in C57BL\/KsJ-db\/db Mice by Oral Administration of the Na+-Glucose Cotransporter Inhibitor T-1095","volume":"132","author":"Arakawa","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1038\/nutd.2014.40","article-title":"Efficacy, Safety and Regulatory Status of SGLT2 Inhibitors: Focus on Canagliflozin","volume":"4","author":"Haas","year":"2014","journal-title":"Nutr. Diabetes"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liu, J., Li, L., Li, S., Jia, P., Deng, K., Chen, W., and Sun, X. (2017). Effects of SGLT2 Inhibitors on UTIs and Genital Infections in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-02733-w"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial Effects of SGLT2 Inhibitors on Fatty Liver in Type 2 Diabetes: A Common Comorbidity Associated with Severe Complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of Human Sodium Glucose Transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The Human Kidney Low Affinity Na+\/Glucose Cotransporter SGLT2: Delineation of the Major Renal Reabsorptive Mechanism for D-Glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the Kidney in Normal Glucose Homeostasis and in the Hyperglycaemia of Diabetes Mellitus: Therapeutic Implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabet. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","article-title":"Physiology of Renal Glucose Handling via SGLT1, SGLT2 and GLUT2","volume":"61","author":"Ghezzi","year":"2018","journal-title":"Diabetologia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1172\/JCI102424","article-title":"Effect of Diabetes and Insulin on the Maximum Capacity of the Renal Tubules to Reabsorb Glucose","volume":"30","author":"Farber","year":"1951","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365517109090668","article-title":"Maximum Tubular Reabsorption Capacity for Glucose and Renal Hemodynamics during Rapid Hypertonic Glucose Infusion in Normal and Diabetic Subjects","volume":"28","author":"Mogensen","year":"1971","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The Tubular Hypothesis of Nephron Filtration and Diabetic Kidney Disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1126\/science.1160406","article-title":"The Crystal Structure of a Sodium Galactose Transporter Reveals Mechanistic Insights into Na+\/Sugar Symport","volume":"321","author":"Faham","year":"2008","journal-title":"Science"},{"key":"ref_42","unstructured":"Ponikowska, B. (2018). Fizjologia Cz\u0142owieka, PZWL Wydawnictwo Lekarskie."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/jpet.114.213454","article-title":"The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves \u03b2-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat","volume":"350","author":"Hansen","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db13-0604","article-title":"Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30\u201350% of Filtered Glucose Load in Humans","volume":"62","author":"DeFronzo","year":"2013","journal-title":"Diabetes"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and Safety of Sodium Glucose Co-Transport-2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0888-7543(89)90333-9","article-title":"Assignment of the Human Intestinal Na+\/Glucose Cotransporter Gene (SGLT1) to the q11.2\u2192qter Region of Chromosome 22","volume":"4","author":"Hediger","year":"1989","journal-title":"Genomics"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1006\/geno.1993.1399","article-title":"Assignment of the Human Na+\/Glucose Cotransporter Gene SGLT1 to Chromosome 22q13.1","volume":"17","author":"Turk","year":"1993","journal-title":"Genomics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"15204","DOI":"10.1016\/S0021-9258(17)36592-4","article-title":"Structure of the Human Na+\/Glucose Cotransporter Gene SGLT1","volume":"269","author":"Turk","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2018: A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and Safety of Sodium\u2013Glucose Co-Transporter-2 Inhibitors in Type 2 Diabetes Mellitus: Systematic Review and Network Meta-Analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s13300-017-0274-3","article-title":"Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM)","volume":"8","author":"Matsumura","year":"2017","journal-title":"Diabetes Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/dom.12481","article-title":"Effects of Luseogliflozin, a Sodium\u2013Glucose Co-Transporter 2 Inhibitor, on 24-h Glucose Variability Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study","volume":"17","author":"Nishimura","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin Lowers Plasma Glucose Concentration and Improves \u03b2-Cell Function","volume":"100","author":"Merovci","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin Improves Muscle Insulin Sensitivity but Enhances Endogenous Glucose Production","volume":"124","author":"Merovci","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1210\/jc.2015-2597","article-title":"Effect of Dapagliflozin with and without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males","volume":"101","author":"Merovci","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/DMSO.S233538","article-title":"Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence","volume":"13","author":"Bonora","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_58","unstructured":"American Diabetes Association (2024). Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes\u20142024. Diabetes Care, 47, S122\u2013S137."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12459","article-title":"Long-Term Glycaemic Response and Tolerability of Dapagliflozin versus a Sulphonylurea as Add-On Therapy to Metformin in Patients with Type 2 Diabetes: 4-Year Data","volume":"17","author":"Nauck","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.2337\/db16-1602","article-title":"Dual Regulation of Gluconeogenesis by Insulin and Glucose in the Proximal Tubules of the Kidney","volume":"66","author":"Sasaki","year":"2017","journal-title":"Diabetes"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the Glucose Transporter SGLT2 with Dapagliflozin in Pancreatic Alpha Cells Triggers Glucagon Secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic Response to Sodium\u2013Glucose Cotransporter 2 Inhibition in Type 2 Diabetic Patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV Protection in the EMPA-REG OUTCOME Trial: A \u201cThrifty Substrate\u201d Hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., and Tentolouris, N. (2019). SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16162965"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1038\/nutd.2014.20","article-title":"Tofogliflozin, a Sodium\/Glucose Cotransporter 2 Inhibitor, Attenuates Body Weight Gain and Fat Accumulation in Diabetic and Obese Animal Models","volume":"4","author":"Suzuki","year":"2014","journal-title":"Nutr. Diabetes"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/a-0958-2441","article-title":"Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes","volume":"51","author":"Wu","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr. Diab. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e98720","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 Inhibitor Dapagliflozin Limits Podocyte Damage in Proteinuric Nondiabetic Nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1091\/mbc.E15-04-0223","article-title":"Angiotensin II Down-Regulates Nephrin\u2013Akt Signaling and Induces Podocyte Injury: Role of c-Abl","volume":"27","author":"Yang","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"ref_70","unstructured":"Thomson, S.C., and Vallon, V. (2020, January 22\u201325). Renal Effects of Sodium\u2013Glucose Co-Transporter Inhibitors. Proceedings of the American Society of Nephrology Kidney Week, Virtual."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of Diabetic Kidney Disease: Impact of SGLT2 Inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00125-003-1155-z","article-title":"Reactive Oxygen Species Cause Diabetes-Induced Decrease in Renal Oxygen Tension","volume":"46","author":"Palm","year":"2003","journal-title":"Diabetologia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00125-004-1434-3","article-title":"Polyol-Pathway-Dependent Disturbances in Renal Medullary Metabolism in Experimental Insulin-Deficient Diabetes Mellitus in Rats","volume":"47","author":"Palm","year":"2004","journal-title":"Diabetologia"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 Inhibitor Empagliflozin Reduces Renal Growth and Albuminuria in Proportion to Hyperglycemia and Prevents Glomerular Hyperfiltration in Diabetic Akita Mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","article-title":"Knockout of Na-Glucose Transporter SGLT2 Attenuates Hyperglycemia and Glomerular Hyperfiltration but Not Kidney Growth or Injury in Diabetes Mellitus","volume":"304","author":"Vallon","year":"2013","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/bph.12269","article-title":"Tofogliflozin, a Novel Sodium\u2013Glucose Co-Transporter 2 Inhibitor, Improves Renal and Pancreatic Function in db\/db Mice","volume":"170","author":"Nagata","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C.S., Nishii, N., and Yamada, H. (2014). Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db\/db Mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100777"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1124\/jpet.113.203869","article-title":"Effects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats","volume":"345","author":"Kojima","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Gangadharan Komala, M., Gross, S., Mudaliar, H., Huang, C., Pegg, K., Mather, A., Shen, S., Pollock, C.A., and Panchapakesan, U. (2014). Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0108994"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin: A Glucose-Regulating Drug with Diuretic Properties in Subjects with Type 2 Diabetes","volume":"15","author":"Wie","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/1753-0407.13405","article-title":"Effects of First-Line Antidiabetic Drugs on the Improvement of Arterial Stiffness: A Bayesian Network Meta-Analysis","volume":"15","author":"Wang","year":"2023","journal-title":"J. Diabetes"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Tassone, F., Ferreri, C., Rossi, A., Borretta, G., Pastorini, G., Anastasio, F., and Feola, M. (Endocr. Metab. Immune Disord. Drug Targets, 2025). Empagliflozin and Arterial Stiffness in Patients with Type 2 Diabetes: A Real-World Case-Control Study, Endocr. Metab. Immune Disord. Drug Targets, Epub ahead of printing.","DOI":"10.2174\/0118715303372020250131060159"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12933-019-0839-8","article-title":"How Does Empagliflozin Improve Arterial Stiffness in Patients with Type 2 Diabetes Mellitus? Subanalysis of a Clinical Trial","volume":"18","author":"Bosch","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"108781","DOI":"10.1016\/j.jdiacomp.2024.108781","article-title":"The Effect of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Arterial Stiffness: A Meta-Analysis of Randomized Controlled Trials","volume":"38","author":"Rizos","year":"2024","journal-title":"J. Diabetes Complicat."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","article-title":"Multi-Dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics","volume":"25","author":"Puchalska","year":"2017","journal-title":"Cell Metab."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of Oxidative Stress by \u03b2-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-nutr-071816-064916","article-title":"\u03b2-Hydroxybutyrate: A Signaling Metabolite","volume":"37","author":"Newman","year":"2017","journal-title":"Annu. Rev. Nutr."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.numecd.2013.12.008","article-title":"The Low-Carbohydrate Diet and Cardiovascular Risk Factors: Evidence from Epidemiologic Studies","volume":"24","author":"Hu","year":"2014","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium\u2013Glucose Cotransporter Inhibitors and Oxidative Stress: An Update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of Dapagliflozin on Ventricular Arrhythmias, Resuscitated Cardiac Arrest, or Sudden Death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Cappetta, D., De Angelis, A., Bellocchio, G., Telesca, M., Cianflone, E., Torella, D., Rossi, F., Urbanek, K., and Berrino, L. (2021). Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.810791"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., and Docimo, G. (2022). An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073651"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11892-024-01572-0","article-title":"Impact of SGLT2 Inhibitors on Lipoproteins in Type 2 Diabetes","volume":"25","author":"Corral","year":"2025","journal-title":"Curr. Diabetes Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"105068","DOI":"10.1016\/j.phrs.2020.105068","article-title":"Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Lipid Profile: A Systematic Review and Meta-Analysis of 48 Randomized Controlled Trials","volume":"160","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"117236","DOI":"10.1016\/j.atherosclerosis.2023.117236","article-title":"SGLT2-Inhibition Increases Total, LDL, and HDL Cholesterol and Lowers Triglycerides: Meta-Analyses of 60 Randomized Trials, Overall and by Dose, Ethnicity, and Drug Type","volume":"394","author":"Bechmann","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.dsx.2019.01.016","article-title":"Lipid Profile in Type 2 Diabetic Patients with New Dapagliflozin Treatment; Actual Clinical Experience Data of Six Months Retrospective Lipid Profile from Single Center","volume":"13","author":"Calapkulu","year":"2019","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s40200-023-01305-2","article-title":"Empagliflozin Improves High-Sensitive Cardiac Troponin-I and High-Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: A Post-Hoc Analysis of EMPA-CARD Trial","volume":"22","author":"Taheri","year":"2023","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1111\/dom.15046","article-title":"Efficacy and Safety of Enavogliflozin, a Novel SGLT2 Inhibitor, in Korean People with Type 2 Diabetes: A 24-Week, Multicentre, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial","volume":"25","author":"Kwak","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"106667","DOI":"10.1016\/j.phrs.2023.106667","article-title":"Neutral Effect of SGLT2 Inhibitors on Lipoprotein Metabolism: From Clinical Evidence to Molecular Mechanisms","volume":"188","author":"Osto","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of Increased LDL and Decreased Triglycerides with SGLT2 Inhibition","volume":"38","author":"Basu","year":"2019","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Albitar, O., D\u2019Souza, C.M., and Adeghate, E.A. (2024). Effects of Lipoproteins on Metabolic Health. Nutrients, 16.","DOI":"10.3390\/nu16132156"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-016-0491-5","article-title":"Dapagliflozin Decreases Small Dense Low-Density Lipoprotein-Cholesterol and Increases High-Density Lipoprotein 2-Cholesterol in Patients with Type 2 Diabetes: Comparison with Sitagliptin","volume":"16","author":"Hayashi","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 Inhibitor Empagliflozin in Patients Hospitalized for Acute Heart Failure: A Multinational Randomized Trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after Acute Myocardial Infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcjd.2014.10.013","article-title":"Uric Acid as a Biomarker and a Therapeutic Target in Diabetes","volume":"39","author":"Lytvyn","year":"2015","journal-title":"Can. J. Diabetes"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1152\/ajprenal.00555.2014","article-title":"Glycosuria-Mediated Urinary Uric Acid Excretion in Patients with Uncomplicated Type 1 Diabetes Mellitus","volume":"308","author":"Lytvyn","year":"2015","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_118","first-page":"13","article-title":"Risk Factor Control Is Key in Diabetic Nephropathy","volume":"258","author":"Lewis","year":"2014","journal-title":"Practitioner"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2015.11.026","article-title":"Uric Acid in Metabolic Syndrome: From an Innocent Bystander to a Central Player","volume":"29","author":"Kanbay","year":"2016","journal-title":"Eur. J. Intern. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MNH.0b013e32832ee3de","article-title":"Solute Carrier Family 2, Member 9 and Uric Acid Homeostasis","volume":"18","author":"Cheeseman","year":"2009","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"20406223221083509","DOI":"10.1177\/20406223221083509","article-title":"Effect of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors on Serum Urate Levels in Patients with and without Diabetes: A Systematic Review and Meta-Regression of 43 Randomized Controlled Trials","volume":"13","author":"Yip","year":"2022","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jacc.2023.10.030","article-title":"Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure","volume":"83","author":"Packer","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"109506","DOI":"10.1016\/j.cellsig.2019.109506","article-title":"Empagliflozin Reduces High Glucose-Induced Oxidative Stress and miR-21-Dependent TRAF3IP2 Induction and RECK Suppression, and Inhibits Human Renal Proximal Tubular Epithelial Cell Migration and Epithelial-to-Mesenchymal Transition","volume":"68","author":"Das","year":"2020","journal-title":"Cell. Signal."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Pirklbauer, M., Sallaberger, S., Staudinger, P., Corazza, U., Leierer, J., Mayer, G., and Schramek, H. (2021). Empagliflozin Inhibits IL-1\u03b2-Mediated Inflammatory Response in Human Proximal Tubular Cells. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105089"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"A1830","DOI":"10.1016\/S0735-1097(18)32371-4","article-title":"Empagliflozin and Canagliflozin Attenuate Inflammatory Cytokines Interferon-\u03bb, Tumor Necrosis Factor-\u03b1, Interleukin-6: Possible Mechanism of Decreasing Cardiovascular Risk in Diabetes Mellitus","volume":"71","author":"Tan","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcp.26851","article-title":"Sodium\u2013Glucose Cotransporter 2 Inhibitors and Inflammation in Chronic Kidney Disease: Possible Molecular Pathways","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a Selective SGLT2 Inhibitor, Attenuated Cardiac Fibrosis by Regulating the Macrophage Polarization via STAT3 Signaling in Infarcted Rat Hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of Canagliflozin versus Glimepiride on Adipokines and Inflammatory Biomarkers in Type 2 Diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"355","DOI":"10.14740\/jocmr4510","article-title":"Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus","volume":"13","author":"Shaheer","year":"2021","journal-title":"J. Clin. Med. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jacc.2008.05.060","article-title":"Leptin Resistance","volume":"52","author":"Martin","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 Inhibitors on Systemic and Tissue Low-Grade Inflammation: The Potential Contribution to Diabetes Complications and Cardiovascular Disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1210\/clinem\/dgaa057","article-title":"Dapagliflozin Suppresses Hepcidin and Increases Erythropoiesis","volume":"105","author":"Ghanim","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","article-title":"Mechanisms of Enhanced Renal and Hepatic Erythropoietin Synthesis by Sodium\u2013Glucose Cotransporter 2 Inhibitors","volume":"44","author":"Packer","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Tziastoudi, M., Pissas, G., Golfinopoulos, S., Filippidis, G., Dousdampanis, P., Eleftheriadis, T., and Stefanidis, I. (2023). Sodium\u2013Glucose Transporter 2 (SGLT2) Inhibitors and Iron Deficiency in Heart Failure and Chronic Kidney Disease: A Literature Review. Life, 13.","DOI":"10.3390\/life13122338"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e14632","DOI":"10.1111\/dme.14632","article-title":"Successful Withdrawal of Erythropoiesis-Stimulating Agent after Administration of an SGLT2 Inhibitor, Tofogliflozin, in People with Diabetes","volume":"39","author":"Sato","year":"2022","journal-title":"Diabet. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s13300-018-0447-8","article-title":"There Is a Close Association between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study","volume":"9","author":"Kinoshita","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The Global Epidemiology of NAFLD and NASH in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study with 8-Week Treatment in Type 2 Diabetes Patients","volume":"42","author":"Honka","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2018.03.043","article-title":"Canagliflozin Protects against Non-Alcoholic Steatohepatitis in Type-2 Diabetic Rats through Zinc Alpha-2 Glycoprotein Up-Regulation","volume":"828","author":"Kabil","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Liao, X., Wang, X., Li, H., Li, L., Zhang, G., Yang, M., Yuan, L., Liu, H., Yang, G., and Gao, L. (2016). Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-\u03b12-Glycoprotein Levels in Patients with Type 2 Diabetes. Sci. Rep., 6.","DOI":"10.1038\/srep32887"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1152\/physrev.00032.2015","article-title":"Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans","volume":"96","author":"Kullmann","year":"2016","journal-title":"Physiol. Rev."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jdi.12087","article-title":"Diabetes Mellitus and Risk of Dementia: A Meta-Analysis of Prospective Observational Studies","volume":"4","author":"Gudala","year":"2013","journal-title":"J. Diabetes Investig."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13098-024-01346-4","article-title":"The Relationship between Diabetes and the Dementia Risk: A Meta-Analysis","volume":"16","author":"Cao","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41580-024-00753-9","article-title":"Cellular and Pathological Functions of Tau","volume":"25","author":"Naguib","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Iannantuoni, F., De Mara\u00f1on, A.M., Diaz-Morales, N., Falcon, R., Ba\u00f1uls, C., Abad-Jimenez, Z., Victor, V.M., Hernandez-Mijares, A., and Rovira-Llopis, S. (2019). The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111814"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s13300-024-01538-1","article-title":"Risk of Dementia in Patients with Diabetes Using Sodium-Glucose Transporter 2 Inhibitors (SGLT2i): A Systematic Review, Meta-Analysis, and Meta-Regression","volume":"15","author":"Gunawan","year":"2024","journal-title":"Diabetes Ther."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Youn, Y.J., Kim, S., Jeong, H.-J., Ah, Y.-M., and Yu, Y.M. (2024). Sodium-Glucose Cotransporter-2 Inhibitors and Their Potential Role in Dementia Onset and Cognitive Function in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Front. Neuroendocrinol., 73.","DOI":"10.1016\/j.yfrne.2024.101131"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2017.08.013","article-title":"Canagliflozin Prevents Scopolamine-Induced Memory Impairment in Rats: Comparison with Galantamine Hydrobromide Action","volume":"277","author":"Arafa","year":"2017","journal-title":"Chem. Biol. Interact."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic Control with Empagliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorates Cardiovascular Injury and Cognitive Dysfunction in Obese and Type 2 Diabetic Mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40035-024-00431-y","article-title":"SGLT2 Inhibitors: A Novel Therapy for Cognitive Impairment via Multifaceted Effects on the Nervous System","volume":"13","author":"Mei","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Erdogan, M.A., Yusuf, D., Christy, J., Solmaz, V., Erdogan, A., Taskiran, E., and Erbas, O. (2018). Highly Selective SGLT2 Inhibitor Dapagliflozin Reduces Seizure Activity in Pentylenetetrazol-Induced Murine Model of Epilepsy. BMC Neurol., 18.","DOI":"10.1186\/s12883-018-1086-4"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"d4092","DOI":"10.1136\/bmj.d4092","article-title":"Factors Associated with the Presence of Diabetic Ketoacidosis at Diagnosis of Diabetes in Children and Young Adults: A Systematic Review","volume":"343","author":"Thompson","year":"2011","journal-title":"BMJ"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 Inhibitor\u2013Associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment with Sodium\u2013Glucose Cotransporter 2 Inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.diabres.2017.04.004","article-title":"Incidence of Diabetic Ketoacidosis among Patients with Type 2 Diabetes Mellitus Treated with SGLT2 Inhibitors and Other Antihyperglycemic Agents","volume":"128","author":"Wang","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jcjd.2020.08.100","article-title":"Prevalence and Clinical Characteristics of Adults Presenting with Sodium-Glucose Cotransporter-2 Inhibitor-Associated Diabetic Ketoacidosis at a Canadian Academic Tertiary Care Hospital","volume":"45","author":"Clark","year":"2021","journal-title":"Can. J. Diabetes"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2337\/dc15-1251","article-title":"Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program","volume":"38","author":"Erondu","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/phar.1881","article-title":"SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature","volume":"37","author":"Burke","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_159","first-page":"e29652","article-title":"A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis","volume":"14","author":"Patel","year":"2022","journal-title":"Cureus"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","article-title":"Clinical Adverse Events Associated with Sodium\u2013Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals","volume":"106","author":"Lin","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_161","unstructured":"U.S. Food and Drug Administration (2025, September 24). FDA Drug Safety Communication: FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections, Available online: https:\/\/www.fda.gov\/drugs."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1161\/CIR.0000000000001285","article-title":"2024 AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"150","author":"Thompson","year":"2024","journal-title":"Circulation"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2025). 16. Diabetes Care in the Hospital: Standards of Care in Diabetes\u20142025. Diabetes Care, 48, S321\u2013S334.","DOI":"10.2337\/dc25-S016"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.123.065748","article-title":"Blinded Withdrawal of Long-Term Randomized Treatment with Empagliflozin or Placebo in Patients with Heart Failure","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and Urinary Tract Infections in Diabetes: Impact of Pharmacologically-Induced Glucosuria","volume":"103","author":"Geerlings","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e6944","DOI":"10.1097\/MD.0000000000006944","article-title":"Safety and Efficiency of SGLT2 Inhibitor Combining with Insulin in Subjects with Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"96","author":"Yang","year":"2017","journal-title":"Medicine"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e074068","DOI":"10.1136\/bmj-2022-074068","article-title":"Benefits and Harms of Drug Treatment for Type 2 Diabetes: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials","volume":"381","author":"Shi","year":"2023","journal-title":"BMJ"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s13300-020-00803-3","article-title":"Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials","volume":"11","author":"Patel","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium\u2013Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier Gangrene Associated with Sodium\u2013Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases","volume":"170","author":"Chamberlain","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/dom.14082","article-title":"Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk of Urosepsis: A Multi-Site, Prevalent New-User Cohort Study","volume":"22","author":"Fisher","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e2903","DOI":"10.1002\/dmrr.2903","article-title":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Fracture Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis","volume":"33","author":"Ruanpeng","year":"2017","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/dom.12742","article-title":"Lack of Evidence for a Harmful Effect of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors on Fracture Risk among Type 2 Diabetes Patients: A Network and Cumulative Meta-Analysis of Randomized Controlled Trials","volume":"18","author":"Tang","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1111\/dom.15220","article-title":"The Associations of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors as Add-On to Metformin with Fracture Risk in Patients with Type 2 Diabetes Mellitus","volume":"25","author":"Driessen","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Mostafa, M.E.A., and Alrasheed, T. (2024). Risk of Bone Fracture by Using Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Network Meta-Analysis of Population-Based Cohort Studies. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1410883"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium Glucose Cotransporter 2 Inhibitors and Risk of Serious Adverse Events: Nationwide Register-Based Cohort Study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.diabet.2018.02.001","article-title":"Risks of Diabetic Foot Syndrome and Amputation Associated with Sodium Glucose Co-Transporter 2 Inhibitors: A Meta-Analysis of Randomized Controlled Trials","volume":"44","author":"Li","year":"2018","journal-title":"Diabetes Metab."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.clinthera.2016.03.031","article-title":"Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes","volume":"38","author":"Kohler","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/dom.13124","article-title":"Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Safety Data from Phase IIb\/III Clinical Trials","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2017). 8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care, 40, S64\u2013S74.","DOI":"10.2337\/dc17-S011"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 Inhibitors and Risk of Cancer in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/dom.13745","article-title":"Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors and Cancer: A Meta-Analysis of Randomized Controlled Trials","volume":"21","author":"Dicembrini","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of Diabetes on the Effects of Sodium Glucose Co-Transporter-2 Inhibitors on Kidney Outcomes: Collaborative Meta-Analysis of Large Placebo-Controlled Trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Wang, Q., Yu, J., Deng, W., Liu, C., Yang, J., Li, Y., Cai, G., Chen, X., and Dong, Z. (2024). Influence of Sodium\/Glucose Cotransporter-2 Inhibitors on the Incidence of Acute Kidney Injury: A Meta-Analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1372421"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). With the Special Contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_186","first-page":"e263","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm\u20132023 Update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr. Pract."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2025). 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142025. Diabetes Care, 48, S207\u2013S238.","DOI":"10.2337\/dc25-S010"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/20\/4125\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:13:39Z","timestamp":1761192819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/20\/4125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":190,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["molecules30204125"],"URL":"https:\/\/doi.org\/10.3390\/molecules30204125","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]}}}